Loss of Bcl-2 expression correlates with tumour recurrence in colorectal cancer

Gut

Volumn 43, Issue 3, 1998, Pages 383-387

  Ilyas, M ^a   Hao, X P ^b   Wilkinson, K ^b   Tomlinson, I P M ^c   Abbasi, A M ^b   Forbes, A ^b   Bodmer, W F ^a   Talbot, I C ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ST MARK S HOSPITAL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Bcl 2; Colorectal cancer; Jass grouping; P53; Tumour recurrence

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN BCL 2; PROTEIN P53;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER STAGING; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TUMOR SUPPRESSOR GENE;

EID: 0031711217     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.43.3.383     Document Type: Article

References (26)

1. Potter JD, Slattery ML, Bostick RM, et al. Colon cancer: a review of the epidemiology. Epidemiol Rev 1993;15:499-545.
2. Jass JR, Love SB, Northover JM. A new prognostic classification of rectal cancer. Lancet 1987;i:1303-6.
3. Hockenbery D, Nunez G, Milliman C, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
4. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992;80:879-86.
5. Tsujimoto Y, Cossman J, Jaffe E, et al. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985; 228:1440-3.
6. Weiss LM, Warnke RA, Sklar J, et al. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med 1987;317:1185-9.
7. Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143: 390-400.
8. Hague A, Moorghen M, Hicks D, et al. BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene 1994;9:3367-70.
9. Herod JJ, Eliopoulos AG, Warwick J, et al. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996;56:2178-84.
10. Lipponen P, Pietilainen T, Kosma VM, et al. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol 1995;177:49-55.
11. Paraf F, Gogusev J, Chretien Y, et al. Expression of bcl-2 oncoprotein in renal cell tumours. J Pathol 1995;177:247-52.
12. Pezzella F, Turley H, Kuzu I, et al. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993;329: 690-4.
13. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
14. Watson AJ, Merritt AJ, Jones LS, et al. Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Br J Cancer 1996;73:889-95.
15. Ofner D, Riehemann K, Maier H, et al. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer 1995;72:981-5.
16. Lane DP. p53, guardian of the genome. Nature 1992;358: 15-16.
17. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
18. Costa A, Marasca R, Valentinis B, et al. p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers. J Pathol 1995;176:45-53.
19. Nathanson SD, Linden MD, Tender P, et al. Relationship among p53, stage, and prognosis of large bowel cancer. Dis Colon Rectum 1994;37:527-34.
20. Scott N, Sagar P, Stewart J, et al. p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br JCancer 1991;63:317-9.
21. Suzuki H, Matsumoto K, Koide A, et al. Correlation of p53 with the clinicopathologic features and prognosis of colorectal adenocarcinoma. Surg Today 1994;24:85-7.
22. Yamaguchi A, Kurosaka Y, Fushida S, et al. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 1992;70:2778-84.
23. Zeng ZS, Sarkis AS, Zhang ZF, et al. p53 nuclear overexpression: an independent predictor of survival in lymph node-positive colorectal cancer patients. J Clin Oncol 1994;12:2043-50.
24. Ilyas M, Novelli M, Wilkinson K, et al. Tumour recurrence is associated with Jass grouping but not with differences in E-cadherin expression in moderately differentiated Dukes' B colorectal cancers. J Clin Pathol 1997;50:218-22.
25. Ilyas M, Tomlinson IPM, Hanby A, et al. Bcl-2 expression in colorectal tumours: evidence of different pathways in sporadic and ulcerative colitis-associated carcinomas. Am J Pathol 1996;149:1719-26.
26. Shibata D, Reale MA, Lavin P, et al. The DCC protein and prognosis in colorectal-cancer. N Engl J Med 1996;335: 1727-32.